CureDuchenne Ventures

CureDuchenne Ventures operates as the investment arm of CureDuchenne, a national nonprofit dedicated to eradicating Duchenne muscular dystrophy. It deploys a venture philanthropy model, strategically funding research and development initiatives. This approach combines philanthropic intent with a business-oriented strategy, efficiently allocating capital to promising therapeutic avenues.

Debra and Paul Miller founded the organization in 2003. Their personal journey began with their son's diagnosis, revealing a critical gap in traditional charitable models for accelerating Duchenne research. This foundational insight spurred them to establish a novel nonprofit structure, leveraging business acumen to drive scientific progress.

CureDuchenne Ventures primarily supports the Duchenne community, including patients and their families, by fostering innovation in research and improving care. Its overarching mission is to advance groundbreaking science and therapeutics, bringing hope and solutions to those affected. The company envisions a future where Duchenne muscular dystrophy is curable.